Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics Inc (NQ: STOK )

10.92 +0.31 (+2.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 75,423
Open 10.62
Bid (Size) 10.62 (1)
Ask (Size) 11.67 (1)
Prev. Close 10.61
Today's Range 10.62 - 11.09
52wk Range 6.880 - 22.87
Shares Outstanding 44,188,534
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Analysts Have This to Say About Stoke Therapeutics
 
Via Benzinga
Where Stoke Therapeutics Stands With Analysts
 
Via Benzinga

Performance

YTD
+20.13%
+20.13%
1 Month
+10.64%
+10.64%
3 Month
+25.95%
+25.95%
6 Month
+48.77%
+48.77%
1 Year
-9.83%
-9.83%

More News

Read More
Stoke Therapeutics: Q1 Earnings Insights
Via Benzinga
Adobe And 2 Other Stocks Insiders Are Selling
Via Benzinga
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the BofA Securities Health Care Conference
From Stoke Therapeutics, Inc.
Via Business Wire
What 7 Analyst Ratings Have To Say About Stoke Therapeutics
Via Benzinga
Credit Suisse Maintains Outperform Rating for Stoke Therapeutics: Here's What You Need To Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
From Stoke Therapeutics, Inc.
Via Business Wire
6 Analysts Have This to Say About Stoke Therapeutics
Via Benzinga
Expert Ratings for Stoke Therapeutics
Via Benzinga
Stoke Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Participate at Upcoming March Investor Conferences
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Yum! Brands To Rally Around 20%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.